Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer.

Urology

Volumn 57, Issue 4, 2001, Pages

  Saint, F ^a   Patard, J J ^a   Irani, J ^a   Salomon, L ^a   Hoznek, A ^a   Legrand, P ^a   Debois, H ^a   Abbou, C C ^a   Chopin, D K ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG CONNAUGHT; BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER STAGING; CARCINOMA IN SITU; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MIDDLE AGED; PATHOLOGY; PERCEPTION; ROC CURVE; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; URINE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAVITY PERCEPTION; HUMANS; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ROC CURVE; URINARY BLADDER NEOPLASMS; URINE;

MLCS; MLOWN;

EID: 0035321284     PISSN: None     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/s0090-4295(01)00921-9     Document Type: Article

References (0)